Chronicling the COPD Patient Journey and change in COPD symptoms, quality of life and exacerbations following initiation of Budenoside/Glycopyrronium/Formoterol [BGF] - CHRONICLES

Exclusion Criteria

• • Diagnosis of asthma
• • Dementia or other health issues related to memory
• • Inability to use inhalers
• • COPD due to documented α-1 antitrypsin deficiency
• • Previous treatment with triple fixed-dose combination therapy in 12 months prior to screening visit
• • Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment
• • Pregnancy or lactation period
• • Participation in an ongoing clinical interventional or observational trial for another COPD medication (or completed another trial within last 30 days of initiating BGF)
• • Patient self-reporting or a physician record with an active COVID-19 infection at time of enrolment or hospitalized due to COVID-19 infection in the last 60 days
• • Previous enrolment in this study